Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : hAd5 S+N
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Agreement
Amyris and ImmunityBio Complete Joint Venture for Next Generation COVID-19 RNA Vaccine
Details : The ability to ‘mix and match’ vaccine platforms through this new joint venture and ImmunityBio’s multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19 including hAd5 S+N.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 03, 2022
Lead Product(s) : hAd5 S+N
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : ImmunityBio
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : RNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Amyris Achieves Promising in-vivo Results for Intranasal RNA Vaccine
Details : The Amyris/IDRI RNA technology may also support the potential for intranasal vaccine delivery that can protect against SARS-CoV-2 and other respiratory diseases, including the flu.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 20, 2021
Lead Product(s) : RNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary data from a pre-clinical study of IDRI's Nanostructured Lipid Carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the COVID-19 spike protein using a self-adjuvanting RNA vaccine.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 22, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Infectious Disease Research Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?